Tenax Therapeutics, Inc. downgraded to Hold ahead of Aug 2026 phase 3 TNX-103 data in PH-HFpEF; weigh 6MWD odds, downside, ...
Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results